Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial
- PMID: 27838190
- DOI: 10.1016/S1474-4422(16)30294-0
Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial
Abstract
Background: Infantile spasms constitutes a severe infantile epilepsy syndrome that is difficult to treat and has a high morbidity. Hormonal therapies or vigabatrin are the most commonly used treatments. We aimed to assess whether combining the treatments would be more effective than hormonal therapy alone.
Methods: In this multicentre, open-label randomised trial, 102 hospitals (Australia [three], Germany [11], New Zealand [two], Switzerland [three], and the UK [83]) enrolled infants who had a clinical diagnosis of infantile spasms and a hypsarrhythmic (or similar) EEG no more than 7 days before enrolment. Participants were randomly assigned (1:1) by a secure website to receive hormonal therapy with vigabatrin or hormonal therapy alone. If parents consented, there was an additional randomisation (1:1) of type of hormonal therapy used (prednisolone or tetracosactide depot). Block randomisation was stratified for hormonal treatment and risk of developmental impairment. Parents and clinicians were not masked to therapy, but investigators assessing electro-clinical outcome were masked to treatment allocation. Minimum doses were prednisolone 10 mg four times a day or intramuscular tetracosactide depot 0·5 mg (40 IU) on alternate days with or without vigabatrin 100 mg/kg per day. The primary outcome was cessation of spasms, which was defined as no witnessed spasms on and between day 14 and day 42 from trial entry, as recorded by parents and carers in a seizure diary. Analysis was by intention to treat. The trial is registered with The International Standard Randomised Controlled Trial Number (ISRCTN), number 54363174, and the European Union Drug Regulating Authorities Clinical Trials (EUDRACT), number 2006-000788-27.
Findings: Between March 7, 2007, and May 22, 2014, 766 infants were screened and, of those, 377 were randomly assigned to hormonal therapy with vigabatrin (186) or hormonal therapy alone (191). All 377 infants were assessed for the primary outcome. Between days 14 and 42 inclusive no spasms were witnessed in 133 (72%) of 186 patients on hormonal therapy with vigabatrin compared with 108 (57%) of 191 patients on hormonal therapy alone (difference 15·0%, 95% CI 5·1-24·9, p=0·002). Serious adverse reactions necessitating hospitalisation occurred in 33 infants (16 on hormonal therapy alone and 17 on hormonal therapy with vigabatrin). The most common serious adverse reaction was infection occurring in five infants on hormonal therapy alone and four on hormonal therapy with vigabatrin. There were no deaths attributable to treatment.
Interpretation: Hormonal therapy with vigabatrin is significantly more effective at stopping infantile spasms than hormonal therapy alone. The 4 week period of spasm cessation required to achieve a primary clinical response to treatment suggests that the effect seen might be sustained, but this needs to be confirmed at the 18 month follow-up.
Funding: The Castang Foundation, Bath Unit for Research in Paediatrics, National Institute of Health Research, the Royal United Hospitals Bath NHS Foundation Trust, the BRONNER-BENDUNG Stifung/Gernsbach, and University Children's Hospital Zurich.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Comment in
-
Combination therapy for treatment of infantile spasms.Lancet Neurol. 2017 Jan;16(1):19-20. doi: 10.1016/S1474-4422(16)30276-9. Epub 2016 Nov 10. Lancet Neurol. 2017. PMID: 27838191 No abstract available.
-
Hormonal therapy with vigabatrin is superior to hormonal therapy alone in infantile spasms.J Pediatr. 2017 May;184:235-238. doi: 10.1016/j.jpeds.2017.02.051. J Pediatr. 2017. PMID: 28434569 No abstract available.
-
Combined Treatment of 'Vigabatrin and Corticoids' for Infantile Spasms: A Superiority Complex or Truly Superior to Corticoids Monotherapy?Epilepsy Curr. 2017 Nov-Dec;17(6):355-357. doi: 10.5698/1535-7597.17.6.355. Epilepsy Curr. 2017. PMID: 29217977 Free PMC article. No abstract available.
Similar articles
-
Prednisolone or tetracosactide depot for infantile epileptic spasms syndrome? A prospective analysis of data embedded within two randomised controlled trials.Eur J Paediatr Neurol. 2023 Jan;42:110-116. doi: 10.1016/j.ejpn.2022.12.007. Epub 2022 Dec 26. Eur J Paediatr Neurol. 2023. PMID: 36621063
-
Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial.Lancet Child Adolesc Health. 2018 Oct;2(10):715-725. doi: 10.1016/S2352-4642(18)30244-X. Epub 2018 Aug 29. Lancet Child Adolesc Health. 2018. PMID: 30236380 Clinical Trial.
-
Treatment of infantile spasms.Cochrane Database Syst Rev. 2013 Jun 5;2013(6):CD001770. doi: 10.1002/14651858.CD001770.pub3. Cochrane Database Syst Rev. 2013. PMID: 23740534 Free PMC article. Review.
-
Treatment of infantile spasms.Cochrane Database Syst Rev. 2008 Oct 8;(4):CD001770. doi: 10.1002/14651858.CD001770.pub2. Cochrane Database Syst Rev. 2008. Update in: Cochrane Database Syst Rev. 2013 Jun 05;(6):CD001770. doi: 10.1002/14651858.CD001770.pub3. PMID: 18843624 Updated. Review.
-
The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial.Lancet. 2004 Nov 13-19;364(9447):1773-8. doi: 10.1016/S0140-6736(04)17400-X. Lancet. 2004. PMID: 15541450 Clinical Trial.
Cited by
-
Efficacy and Safety of Pulse Intravenous Methylprednisolone in Pediatric Epileptic Encephalopathies: Timing and Networks Consideration.J Clin Med. 2024 Apr 24;13(9):2497. doi: 10.3390/jcm13092497. J Clin Med. 2024. PMID: 38731025 Free PMC article.
-
Epileptic spasms relapse is associated with response latency but not conventional attributes of post-treatment EEG.Epilepsia Open. 2024 Jun;9(3):1034-1041. doi: 10.1002/epi4.12931. Epub 2024 Apr 8. Epilepsia Open. 2024. PMID: 38588009 Free PMC article.
-
Long-term outcomes of infantile spasms in children treated with ketogenic diet therapy in combination with anti-seizure medications in a resource-limited region.Front Epidemiol. 2023 Jan 16;2:1080068. doi: 10.3389/fepid.2022.1080068. eCollection 2022. Front Epidemiol. 2023. PMID: 38455303 Free PMC article.
-
Pharmacokinetics and tissue distribution of vigabatrin enantiomers in rats.Saudi Pharm J. 2024 Feb;32(2):101934. doi: 10.1016/j.jsps.2023.101934. Epub 2023 Dec 23. Saudi Pharm J. 2024. PMID: 38223203 Free PMC article.
-
Initial combination versus early sequential standard therapies for Infantile Epileptic Spasms Syndrome-Feedback from stakeholders.Epilepsia Open. 2024 Apr;9(2):819-822. doi: 10.1002/epi4.12895. Epub 2024 Jan 13. Epilepsia Open. 2024. PMID: 38217384 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical